Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by StockNews.com

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Monday. A number of other equities analysts also recently issued reports on the company. Truist Financial raised their price target on Amneal Pharmaceuticals from $6.00 to $7.00 and […]

Leave a Reply

Your email address will not be published.

Previous post Bel Fuse (NASDAQ:BELFB) PT Raised to $77.00 at Needham & Company LLC
Next post Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com